Interpreting the TOP Study and Comparing FLAURA2 and MARIPOSA Data

This segment interprets the TOP study findings and their practice implications. The panel discusses how the trial's hazard ratios, for both progression-free and overall survival, compare with historical expectations in EGFR-mutated NSCLC and how the trial results impact their current practices. The discussion then situates the TOP study compared with TP53 subgroup findings from the FLAURA2 and MARIPOSA trials. The panel weighs these effect sizes against patient-specific factors and reinforces that identifying the EGFR mutation and TP53 status are useful steps in treatment planning.